Clinical Trial Update: A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the effectiveness, tolerability and safety of laquinimod for relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Laquinimod (laquinimod)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED